Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, ...
A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC). Background: This is an ongoing study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback